Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1464-1478

  Guindon, Josée ^a,b   Guijarro, Ana ^c   Piomelli, Daniele ^c,d   Hohmann, Andrea G ^a,b  

^a University of Georgia   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

2 arachidonoylglycerol; anandamide; cannabinoid antagonists; endocannabinoid levels; formalin; hind paw; inflammatory pain; JZL184; MGL; URB602

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ANALGESIC AGENT; ANANDAMIDE; ENDOCANNABINOID; JZL 184; UNCLASSIFIED DRUG; URB 602;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOACCUMULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONCENTRATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; ED50; ENZYME INHIBITION; EX VIVO STUDY; MALE; MONOTHERAPY; NONHUMAN; PAIN; PAW EDEMA; PRIORITY JOURNAL; RAT;

EID: 84926231211     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01192.x     Document Type: Article

References (62)

1. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al,. (2009). Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16: 411-420.
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al,. (2005). Evidence for novel cannabinoid receptors. Pharmacol Ther 106: 133-145. (Pubitemid 40613055)
4. Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, et al,. (2009). Endocannabinoid Research Group. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta 1791: 53-60.
5. Cadas H, di Tomaso E, Piomelli D, (1997). Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 17: 1226-1242. (Pubitemid 27073726)
6. Calignano A, La Rana G, Giuffrida A, Piomelli D, (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281. (Pubitemid 28335039)
7. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, et al,. (2010). Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 13: 1265-1270.
8. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT, (2002). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260. (Pubitemid 34327871)
9. Coderre TJ, Melzack R, (1992). The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci 12: 3665-3670.
10. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B, (2007). The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 152: 787-794. (Pubitemid 350034978)
11. Costa B, Bettoni I, Petrosino S, Comelli F, Giagnoni G, Di Marzo V, (2010). The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl- serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol Res 61: 537-546.
12. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB, (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87. (Pubitemid 26374593)
13. De Léan A, Munson PJ, Rodbard D, (1978). Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97-E102. (Pubitemid 9159876)
14. Desroches J, Guindon J, Lambert C, Beaulieu P, (2008). Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155: 913-924.
15. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC, (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613. (Pubitemid 19007296)
16. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al,. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949. (Pubitemid 23026736)
17. Di Marzo V, (2006). Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 160: 1-24.
18. Draper NR, Smith H, (1998). Applied Regression Analysis. Wiley: New York.
19. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, Mackie K, et al,. (2007). Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 282: 1518-1528. (Pubitemid 47076553)
20. Gaoni Y, Mechoulam R, (1964). Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
21. 123I-labellded AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 307: 331-338. (Pubitemid 26233375)
22. Giuffrida A, Rodriguez de Fonseca F, Piomelli D, (2000). Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 280: 87-93. (Pubitemid 30210816)
23. Goparaju SK, Ueda N, Taniguchi K, Yamamoto S, (1999). Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57: 417-423. (Pubitemid 29065290)
24. Guindon J, Hohmann AG, (2009). The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8: 403-421.
25. 2 receptors. Br J Pharmacol 150: 693-701. (Pubitemid 46440208)
26. Guindon J, Desroches J, Dani M, Beaulieu P, (2007b). Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. Eur J Pharmacol 568: 173-176. (Pubitemid 46976920)
27. Guindon J, Lo Verme J, Piomelli D, Beaulieu P, (2007c). The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB1 and CB2 receptors. Anesth Analg 104: 1563-1569. (Pubitemid 46791304)
28. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG, (2007). Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150: 153-163. (Pubitemid 46160605)
29. Hohmann AG, Herkenham M, (1999a). Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92: 1171-1175. (Pubitemid 29292557)
30. Hohmann AG, Herkenham M, (1999b). Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90: 923-931. (Pubitemid 29156757)
31. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al,. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112. (Pubitemid 40910518)
32. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al,. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098. (Pubitemid 40299921)
33. Jhaveri MD, Richardson D, Chapman V, (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 152: 624-632. (Pubitemid 350034979)
34. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, et al,. (2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55: 85-93.
35. King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, et al,. (2007). URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol 14: 1357-1365. (Pubitemid 350257009)
36. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, et al,. (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330: 902-910.
37. Kreitzer FR, Stella N, (2009). The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther 122: 83-96.
38. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al,. (2009a). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
39. Long JZ, Nomura DK, Cravatt BF, (2009b). Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
40. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, et al,. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150: 766-781. (Pubitemid 46440215)
41. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al,. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
42. Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM, et al,. (2007). Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 27: 2883-2889. (Pubitemid 46438968)
43. Munro S, Thomas KL, Abu-Shaar M, (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
44. Nackley AG, Makriyannis A, Hohmann AG, (2003). Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747-757. (Pubitemid 36694801)
45. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, et al,. (2009). Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl) piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 331: 591-597.
46. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A, (1995). AM630, a competitive cannabinoid receptor antagonist. Life Sci 56: 1949-1955.
47. Petricevic M, Wanek K, Denko CW, (1978). A new mechanical method for measuring rat paw edema. Pharmacology 16: 153-158. (Pubitemid 8256760)
48. Puig S, Sorkin LS, (1996). Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain 64: 345-355. (Pubitemid 26132446)
49. 2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672. (Pubitemid 29087845)
50. Russo R, Lo Verme J, La Rana G, D'Agostino G, Sasso O, Calignano A, et al,. (2007). Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-α receptor agonist GW7647. Eur J Pharmacol 566: 117-119. (Pubitemid 46795485)
51. Saario SM, Salo OM, Nevalainen T, Poso A, Laitinen JT, Järvinen T, et al,. (2005). Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 12: 649-656. (Pubitemid 43142042)
52. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al,. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13: 1113-1119.
53. Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, Campolongo P, et al,. (2008). The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8: 281-288.
54. Spradley JM, Guindon J, Hohmann AG, (2010). Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 62: 249-258.
55. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R, (2005). Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38: 177-188. (Pubitemid 40779571)
56. Tjölsen A, Berge OG, Hunskaar S, Rosland JH, Hole K, (1992). The formalin test: an evaluation of the method. Pain 51: 5-17.
57. Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ, (2007). Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150: 186-191. (Pubitemid 46160608)
58. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P, (2005). Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132: 1093-1102. (Pubitemid 40602543)
59. Wang J, Ueda N, (2009). Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 89: 112-119.
60. Watson GS, Sufka KJ, Coderre TJ, (1997). Optimal scoring strategies and weights for the formalin test in rats. Pain 70: 53-58. (Pubitemid 27128297)
61. Winer BJ, (1971). Statistical Principles in Experimental Design. McGraw-Hill: New York.
62. Zimmermann M, (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110. (Pubitemid 13058546)